ArticleBritish journal of cancer2018

pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.

Gemma N Jones et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.